1. Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan. Issue 4 (10th June 2021) Authors: Yin, Ophelia; Iwata, Hiroji; Lin, Chia‐Chi; Tamura, Kenji; Watanabe, Junichiro; Wada, Russ; Kastrissios, Helen; AbuTarif, Malaz; Garimella, Tushar; Lee, Caleb; Zhang, Lin; Shahidi, Javad; LaCreta, Frank Journal: Clinical pharmacology & therapeutics Issue: Volume 110:Issue 4(2021) Page Start: 986 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Issue 11 (November 2017) Authors: Doi, Toshihiko; Shitara, Kohei; Naito, Yoichi; Shimomura, Akihiko; Fujiwara, Yasuhiro; Yonemori, Kan; Shimizu, Chikako; Shimoi, Tatsunori; Kuboki, Yasutoshi; Matsubara, Nobuaki; Kitano, Atsuko; Jikoh, Takahiro; Lee, Caleb; Fujisaki, Yoshihiko; Ogitani, Yusuke; Yver, Antoine; Tamura, Kenji Journal: Lancet oncology Issue: Volume 18:Issue 11(2017:Nov.) Page Start: 1512 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Issue 6 (June 2019) Authors: Tamura, Kenji; Tsurutani, Junji; Takahashi, Shunji; Iwata, Hiroji; Krop, Ian E; Redfern, Charles; Sagara, Yasuaki; Doi, Toshihiko; Park, Haeseong; Murthy, Rashmi K; Redman, Rebecca A; Jikoh, Takahiro; Lee, Caleb; Sugihara, Masahiro; Shahidi, Javad; Yver, Antoine; Modi, Shanu Journal: Lancet oncology Issue: Volume 20:Issue 6(2019) Page Start: 816 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗